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LABORATORY INVESTIGATION
Tubular basement membrane change occurs pan passu with the
development of cyst formation
FRANK A. CARONE, PAUL F. HOLLENBERG, SAKIE NAKAMURA, PHAIBUL PUNYARIT,
WALTER GLoGowsKI, and GEORGE FLOURET
Departments of Pathology and Physiology, Northwestern University Medical School, Chicago, Illinois, USA
Renal tubular basement membrane change occurs pan passu with the
development of cyst formation. Our previous studies have shown that
2-amino-4, 5-diphenyl thiazole hydrochloride (DPT) administered orally
to rats induces a urine concentrating defect (within I to 2 days) and
progressive, but reversible, cystic change of all collecting tubules
(prominent between 4 and 8 weeks). Cystic change was characterized
by tubular cell and basement membrane changes consisting of alter-
ations in cellular biosynthetic/secretory organdIes, followed by thick-
ening of the basement membrane with marked reduction (--50%) of the
de novo synthesis of sulfated proteoglycans, suggesting that altered
synthesis of tubular basement membrane plays a role in the develop-
ment of cystic disease. In this study, following the administration of
['4C]-DPT in vivo, a major urinary metabolite (> 70%) was isolated by
HPLC and characterized by gas chromatographic-mass spectral and
NMR analyses as 2-amino-4-hydroxyphenyl-5 phenyl thiazole, desig-
nated phenol II. Phenol II was synthesized and administered orally to
rats for four days to compare its biological effects with DPT. Phenol II
induced a significantly greater impairment of concentrating ability and
tubular cystic transformation than DPT. At day 5, in phenol II treated
animals, basement membranes lining cysts were thickened several-fold
and exhibited extensive loss and disorder of ruthenium red binding
sites, indicative of loss of sulfated proteoglycans (heparin sulfate
proteoglycan). The basement membrane changes occurred in tandem
with the development of cystic transformation and strongly suggests
that the basement membrane has a key role in the pathogenesis of PKD.
The findings support the hypothesis that PKD may be due to a defect in
the synthesis/degradation of one or more basement membrane compo-
nents (sulfated proteoglycans) resulting in faulty tubular morphogen-
esis.
Polycystic kidney disease (PKD) is due to multiple, segmen-
tal distentions, often enormous in degree, of the nephron [1—31.
Its etiology and pathogenesis are unknown, but tubular cell
growth [4, 5] and basement membrane alterations [3, 6] have
been implicated in its development. Human forms of PKD are
not inconsequential: the autosomal dominant form has an
incidence of about 1 in 800 and accounts for approximately 10%
of patients on hemodialysis, and the acquired form develops in
about '/2 of patients with end-stage renal disease being treated
with hemodialysis for more than two years.
It has been shown that several chemicals [2, 6, 7] induce
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polycystic kidney disease in experimental animals, which raises
the possibility that tubular cell response to metabolic activation
of a xenobiotic may induce the disease, particularly the ac-
quired type. Few studies have been directed at the metabolic
activation and fate of chemicals that cause this disease. We
have shown that oral administration of 2-amino-4,5-diphenyl
thiazole (DPT) to rats caused renal cystic disease which was
reversible after withdrawal of the drug [3,6,8]. In this study we
have synthesized [14C]-DPT in order to study the in vivo
metabolism of the drug and to characterize its major metabo-
lites excreted in the urine. ['4C]-DPT was fed orally to rats by
gavage and the radioactive products excreted in the urine were
analyzed for DPT and its metabolites by HPLC.
The major urinary metabolite obtained, as revealed by anal-
ysis by mass spectroscopy and by 1H-Fourier transform NMR,
was a phenolic derivative designated Phenol II, generated by
para-aromatic hydroxylation of the phenyl ring at position 4 of
the thiazole ring of DPT. Phenol II and other possible hydroxy-
lated derivatives of DPT were synthesized and their biologic
activity was determined in vivo. Phenol II alone induced cystic
disease in the rat kidney, and it was significantly more active
than the parent compound DPT. Following the administration
of phenol II for four days, cystic change was prominent and
accompanied by marked ultrastructural change and loss of
ruthenium red binding sites in the tubular basement membrane
indicative of loss of sulfated proteoglycans (heparin sulfate-
proteoglycan). These findings support the proposal that tubular
cell-basement membrane interactions are a key factor in the
pathogenesis of PKD.
Methods
['4C]-thiourea (52.5 mCi/mmol) was purchased from New
England Nuclear Corp (Boston, Massachusetts, USA), and
acetonitrile (HPLC grade) from Burdick and Jackson Labora-
tories Inc. (Muskegon, Michigan, USA); other chemicals were
obtained from the Aldrich Chemical Company (Milwaukee,
Wisconsin, USA). For high-performance liquid chromatogra-
phy (HPLC) we used a Waters Associates (Boston, Massachu-
setts, USA) apparatus consisting of a UK6 injector, two Model
4500 solvent pumps, a 660 solvent programmer, a Model 481
variable wavelength detector, a Senorgor 120 recorder (BBC,
Goertz Metrawatt), and a Bondapak C18 analytical column 30 x
0.39 cm). UV absorbance was determined at 280 nm.
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HPLC analysis of ['4C]-DPT and metabolites in urine
Sprague-Dawley white male rats, 200 to 250 g were adminis-
tered by gavage a solution of ['4C]-DPT (100 m in EtOH:H20,
Sp. Act. 4.2 mC/mM, diluted 1:4 with water) at a dosage of 5 pi
of DPT solutionlg of body weight. The rats were placed in
individual metabolic cages and urine was collected for four
hours, centrifuged for 10 minutes at 4,000 rpm and passed
through a Nalgene syrine filter (0.2 to 0.25 mm pore size). The
urine was analyzed by HPLC on a Waters '8C-reverse phase 10
micron column (4.6 x 25 cm). The elution solvents were: A—
0.5% phosphoric acid, and B—40% A + 50% acetonitrile. The
column was eluted using a linear gradient going from 0 to 35%
B in one hour. One major peak, containing more than 70% of
the total radioactivity applied to the column, eluted at 36
minutes. Under these conditions, the DPT did not elute until
after one hour. The peak corresponding to this major metabolite
was collected from a number of HPLC analyses and subjected
to gas chromatographic-mass spectral and NMR analyses.
Mass spectral analysis of DPT and metabolites in urine
Mass spectra were recorded on a Hewlett-Packard 5985 Mass
Spectrometer. The urine samples containing DPT and metabo-
lites were dissolved in methanol and transferred to a solid probe
sample tube. The solvent was removed by evaporation and the
samples were introduced directly into the ion source. For
chemical ionization, methane was used as the reagent gas, and
the instrument was operated at an ionizing energy of 70 eV for
the electron impact ionization studies. As shown in Figure 1, for
DPT the molecular ion at m/e of 252 is predominant, and for the
major urinary metabolite the molecular ion at 268 is predomi-
nant, which is consistent with the incorporation of one atom of
oxygen into the substrate, suggesting monohydroxylation of the
substrate. 'H-Fourier Transform NMR analysis (data not
shown) of the major urinary metabolite was suggestive of a
para-hydroxylation of one of the two phenyl rings of DPT.
The results did not provide sufficient information to deter-
mine which phenyl ring (attached to the 4- or 5-carbon of the
thiazole ring) had been hydroxylated. In order to determine the
position at which DPT had been hydroxylated, the para-hy-
droxylated derivatives of DPT indicated in Figure 2 were
synthesized by reaction of the appropriately hydroxylated
derivatives of desyl chloride with thiourea.
Synthesis of ['4C]-DPT and its phenolic derivatives
['4C]2-amino-4,5-diphenyl thiazole, hydrochloride, ['4C1
DPT. A mixture of ['4C]thiourea (1.4 mg, specific act. 52.5 mCi!
mmol), thiourea (13.6 mg) and desyl chloride (45 mg) in di-
methylformamide (DMF; 20 id), was heated at 170°C for five
minutes. Acetone precipitation and crystallization from isopro-
panol yielded 33 mg of ['4C]-DPT.
2-Amino-4-(4-methoxyphenyl)-5-phenyl thiazole. Benzoins
were converted to desyl chlorides as described for anisbenzoin.
Anisbenzoin (9 mmol), was reacted with thionyl chloride (15
mmol) for 15 minutes, after neutralization with bicarbonate,
4'-methoxy desyl chloride was extracted with ethyl acetate and
coupled to thiourea in DMF at 50° for five minutes. Acetone
precipitation and crystallization from MeOH yielded product,
mp. 242 to 244°. Anal. calcd for C,6H,5N2OC1S: C, 60.3; H,
4.74; N, 8.79. Found: C, 60.6; H, 4.75; N, 8.62.
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Fig. 1. Mass spectral graphs of DPT and its major urinaly metabolite,
phenol II.
2-Amino-4-(4-hydroxyphenyl)-5-phenyl thiazole (Phenol II).
The above derivative was refluxed in 48% HBr-acetic acid for
28 hours. Neutralization with NaOH, extraction with EtOAc,
evaporation of extracts and crystallization of the residue from
i-PrOH yielded phenol II, mp 196 to 198°. Anal. calcd. for
C,5H,2N,SO: C, 67.1; H, 4.51; N, 10.4. Found: C, 67.3: H,
4.46; N, 10.4.
5)(2C(5
C
CS
a)>
CS
a)
a)(CC
CS
C
CS
a)>
CS
a)
a:
M/Z
00
80
60
40
20
N
II NH2
HO
HO
HO / \
NH2
Fig. 2. Chemical structures of DPT and its hydroxylated derivatives
phenol I, II and III.
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2-Amino4-phenyl-5-(4-methoxyphenyl) thiazole. Product was
obtained from benzanisoin, mp 232 to 234°. Anal. calcd. for
C16H14N2S0: C, 60.3; H, 4.74; N, 8.79. Found: C, 60.2; H,
4.76; N, 8.57.
2-Amino-4-phenyl-5-(4-hydroxypheny!) thiazole (Phenol I).
The preceding derivative was deprotected with HBr-acetic
acid, yielding phenol I, 0.397 g, mp 373 to 277°. Anal. calcd. for
C15H12N2S0: C, 67.1; H, 4.51; N, 10.4. Found: C, 66.7 H,
4.74; N, 10.1.
2-Amino-4-,5-di(4,-methoxyphenyl) thiazole. Product was ob-
tained from anisoin, mp 221 to 224°. Anal. calcd. for
C17H17N2O2SC1: C58.5; H, 4.91; N, 8.03. Found: C, 58.7; H,
4.99; N, 7.88.
2-Amino-4,5-di(4-hydroxyphenyl) thiazole (Phenol III). Dime-
thoxy HBr-AcOH gave phenol III, rnp 256 to 260°. Anal. calcd.
for C15H12N202SC1: N, 9.85. Found: N, 9.72.
Morphological and functional changes induced by DPT and
derivatives
Twenty-four male rats, 125 to 150 g, from Charles River
Labs, were divided into a control group and the following drug
treatment groups: DPT, phenol I, phenol II and phenol III. DPT
or each derivative in a daily dose of 1.2 mgmlg of body weight
was suspended in 1 ml of 1% aqueous gum tragacanth and
administered by gavage daily for four days, control animals
received an equivalent dose of gum tragacanth. Treatment was
limited to four days by availability of the phenolic derivatives of
DPT. On day 5 after 16 hours of dehydration, urine osmolality
was determined with a Precision Systems Osmette A. Urine
was collected in individual metabolism cages. On day 5 the
animals were anesthetized with ether, the abdomen was opened
by a midline incision, the vascular pedicle of the right kidney
was clamped and the right kidney was removed. The aorta was
catheterized and the left kidney was perfused with 50 ml of PBS
to remove blood followed by Karnovsky aldehyde fixative [9]
containing 0.2% ruthenium red for five minutes.
For light microscopy, tissue sections were stained with
hematoxylin and eosin and alcian blue. By light microscopy,
the degree of tubular cell and cystic change involving the
collecting ducts in the outer medulla were scored as follows for
control and the three drug-treated groups.
1 0—25 2X
2 25—50 3X
3 50—75 4X
4 75—100 >4X
Cellular change consisted of the modification of normal
epithelial cells to cells with large hyperchromatic nuclei or
flattened undifferentiated cells. Small (1 mm3) pieces of cortex,
outer and inner medulla were processed for electron micros-
copy [8].
Results
Functional and morphological findings
Mter four days of drug treatment, only DPT- and phenol
IT-treated animals developed significant urine concentrating
defects, with mean urine osmolalities of 978 and 688 MOsm,
respectively (Table 1). The loss of urine concentrating ability
induced by phenol II was significantly greater than that due to
DPT (Table 1). Renal weight expressed as percentage of body
weight was significantly increased compared to controls in all
drug treated groups, except for animals treated with phenol I
(Table 1). Mean renal weights as percentage of body weight
were 0.88, 1.19, and 1.28 for phenol III-, DPT-, and phenol
Il-treated groups, respectively, and the value for the phenol
IT-treated group was significantly greater than the values for the
DPT- and phenol Ill-treated groups (Table 1). The phenol
Ill-treated group did not develop a urine concentrating defect
even though minor tubular cellular changes were detected by
light microscopy in the collecting tubules in the outer medulla in
two of four animals (Table 1). Light microscopic changes were
not detected in animals treated with phenol I (Table 1).
Tubular cell and cystic changes involving the collecting
tubules in the outer medulla were present in the DPT and
phenol Il-treated (Fig. 3) groups and there was variation in the
magnitude of these changes between animals in each group. The
tubular cell and cystic changes were considerably more marked
and extensive in the phenol Il-treated group (Fig. 3) compared
to the DPT-treated group. This is emphasized by the findings
that the mean scores for tubular cell and cystic changes were
about three times greater in the phenol Il-treated group com-
pared to the DPT-treated group (Table 1).
In control kidneys, the tubules were of normal diameter in the
cortex and medulla and glomeruli and tubular cells showed no
significant changes (Fig. 3). Cystic changes in DPT- and phenol
Il-treated animals (Fig. 3) were most prominent in the outer
medulla and involved the collecting ducts. Some cystic tubules
were more than four times the normal tubular diameter. Cystic
tubules were lined either by flattened, simplified cells or plump
enlarged cells with large hyperchromatic nuclei containing
prominent nucleoli. In control animals and in all experimental
groups (including DPT- and phenol lI-treated animals) glomer-
ular and tubular basement membranes (BM) and BMs lining
cystic tubules stained uniformly and with the same intensity
with alcian blue.
By electron microscopy, the BM of cystic collecting ducts
were remarkably altered. In control kidneys, the tubular BMs
were compact and of uniform thickness and density with a
normal lattice-like network of ruthenium red (RR) staining
granules (heparin sulfate proteoglycans). In cystic tubules, the
BMs were thickened several-fold, their density was irregular,
their margins were imprecise and RR staining granules were
reduced or lost and disorganized (Figs. 4, 5). In DPT and phenol
Il-treated animals, the BMs of noncystic tubules and peritubu-
lar capillaries were not thickened (Fig. 5).
Discussion
A number of studies have delineated in rat the renal response
to DPT treatment [3, 6, 8, 10-14]. The animals develop an acute
antidiuretic hormone resistant urine concentrating defect and,
between one and two weeks, cells of the collecting ducts in the
outer medulla exhibit focal degeneration, necrosis and in-
creased cell proliferation. Beyond two weeks, progressive PKD
occurs involving all collecting ducts in the outer medulla.
Sequential ultrastructural studies, utilizing cationic probes dur-
ing the development of cystic change revealed, initially, an
Score
Cystic change:
increase in
% Cellular change tubular diameter
Carone et al. Proteoglycans in cystic disease 1037
Table 1. Renal findings in control and drug treated rats
DPT
Fig. 3. Outer medulla of control and 4 day DPT and phenol II treated (PKD) kidneys. In the DPT panel, arrows indicate fusion sites of two
collecting tubules. x 66.
increase and prominence of the subcellular organelles involved
in protein synthesis and extracellular secretion which were
followed by progressive thickening of the tubular basement
membrane (TBM) with loss of alcian blue and ruthenium red
(RR) staining, indicative of loss of sulfated proteoglycans (PG)
[heparin sulfate-proteoglycan (HS-PG)l. Immunofluorescence
studies revealed uneven staining for type IV collagen and
laminin, absent or weak staining for HS-PG, and uniform bright
staining for fibronectin in the interstitium. Biochemical analysis
of isolated, purified TBMs also revealed significant changes in
the chemical composition of BMs from kidneys with DPT-
induced PKD. Recently, we have demonstrated a decreased
(circa 50%) de novo synthesis of cellular and extracellular (BM)
sulfated PGs in cystic kidneys of rats treated with DPT [151.
Collectively, these data suggest that DPT alters the biosynthe-
sis/degradation of one or more BM components, particularly
HS-PG, resulting in a faulty BM.
Since the BMs in DPT-induced PKD are structurally and
chemically altered, cystic transformation might be due to loss of
BM compliance. It has been found, however, that the deforma-
bility and viscoelastic creep of BMs lining cysts induced by
DPT were not significantly different from normal TBMs [161.
In this study ['4C]-DPT was synthesized, administered orally
to rats and the major urinary metabolite, was analyzed by mass
spectroscopy and NMR, which suggested that it was a phenolic
derivative formed by para-hydroxylation of one of the phenyl
rings of DPT. The para-hydroxylated derivatives of DPT were
synthesized and their biological effects were determined in
vivo. Only phenol II, the 4-hydroxyphenyl derivative, induced
renal changes and these were more marked than changes
Urine
Experimental
osmolality
mOsmlkg Renal weight
Tubular changes mean score
group N H20 % body weight Cellular Cystic
Control 4 2597 74 0.77 0.04 0 0
DPT 6 978 l89 1.19 0.l3 1.0 0.9
Phenol II 6 688 55a.b 1.28 0.l0a 2.8 2.7
Phenol I 4 2770 126 0.84 0.03 0 0
Phenol III 4 2591 71 0.88 0.02 0.5 0
Values are means SE.
a P < 0.05 compared to controlbP < 0.05 compared to DPT
CONTROL PHENOL II
'1
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Fig. 4. Electron micrographs of basement membranes (B) ofcollecting tubules stained with ruthenium red (RR) of control (panel A) and 4-day
phenol II treated (panel B) rats. In the control (panel A) there is a normal lattice network of RR stained granules indicative of heparin sulfate
proteoglycans (arrowheads). Following 4 days of phenol II treatment (panel B), RR stained granules are essentially lost and disorganized.
x 103,000.
induced by the parent compound, DPT. Following only four
days of treatment, phenol II induced a significantly greater
degree of impairment of concentrating ability and cystic trans-
formation than DPI'. A noteable observation was the prominent
changes involving the BMs of cystic tubules, which were
thickened several-fold, and displayed loss and disorder of
ruthenium red binding anionic sites, indicative of loss of sul-
fated PGs (HS-PG) [8, 17]. BMs of cystic tubules did bind alcian
blue, a non-specific cationic probe for glycoprotein, suggesting
a preferential effect of phenol II on sulfated PGs in the BM. The
loss of ruthenium red binding in the BM of cystic tubules is
compatible with faulty synthesis and/or degradation of PGs.
The metabolic turnover of PGs is not homogeneous since in
cartilage both slow and fast (half-life of 4 to 5 days) metabolic
pools have been reported [18]. Thus, data in this study suggest
that a pool of TBM PGs in the rat have a fast rate of metabolic
turnover.
Phenol II was considerably more potent than DPT in impair-
ing urine concentrating ability and inducing cystic change,
suggesting that it is a more proximate metabolite than DPT. In
other studies, (unpublished data) phenol II was the major
metabolite generated during the incubation of labeled DPT with
rat liver microsomes and in the circulation following the oral
administration of labeled DPT in vivo. These findings suggest
that DPT is metabolized in the liver and that the major metab-
olite, phenol II, circulates to the kidney, its primary target
organ. Whether phenol II also undergoes further metabolic
activation in the kidney and the nature of the cellular events
leading to PKD remain to be determined.
Microdissections at an early stage of autosomal dominant
PKD [19] reveal that cystic transformation is a localized event
consisting of loss of normal tubular morphogensis accompanied
by cell growth. Altered cell-BM interactions may be central to
the pathogenesis of PKD. The epithelial cell is primarily respon-
sible for synthesis/degradation of BM components [20], and the
composition of the BM, in turn, plays a regulatory role in tissue
morphogenesis and mobility, shape, differentiation, growth and
gene expression of the cell [21—24]. The tubular BM is com-
posed primarily of type IV collagen, laminin and sulfated PGs.
These components have specific binding sites for each other
and for structural components both on the cell surface and in
the underlying dense connective tissue [20]. Since PGs are
distributed in the cell surface membranes, in the BM and in the
connective tissue [25], they may have a unique role in the
hi-directional transmission of signals between the cell and the
extracellular matrix. Thus, the primary event in PKD may be
faulty synthesis of BM constituents, that is, sulfated PGs, with
the formation of an abnormal BM resulting in defective tubular
morphogenesis expressed as cystic transformation and accom-
panied by altered cell differentiation and growth. In autosomal
dominant PKD, BM lining cysts are greatly thickened [26] and
exhibit loss of staining to fluorescent-tagged anti-HS-PG [14].
Wilson et al found morphologic evidence suggesting a defect in
BM synthesis by cyst-derived cells from autosomal dominant
PKD kidneys in vitro [27]. Our recent findings reveal that BM
elaborated by autosomal dominant cyst-derived cells in vitro
demonstrate little staining with ruthenium red, suggesting a loss
of HS-PG compared to BMs elaborated by normal human renal
epithelial cells.
In this study prominent cyst change was induced in the rat
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Fig. 5. Electron micrographs from rats treated for 4 days with phenol II. Basement membranes (CB) of cystic tubules (C in panels A and B)
are thickened several.fold compared to the basement membranes of a noncystic tubule (B in Panel A) or a peritubular capillary (B in Panel B)
(RBC = red blood cell). x 24,000.
kidney after only four days of treatment with phenol II, a binding sites indicative of a marked change in HS-PG content
hydroxylated derivative of DPT. This was accompanied by and/or distribution in the BM. Highly significant is the obser-
striking tubular BM changes, including loss of ruthenium red vation that TBM changes occurred pan passu with cystic
1040 Carone et a!: Proteoglycans in cystic disease
transformation of the tubule. These findings provide strong
evidence that BM alterations are a key factor in the develop-
ment of cystic disease. A primary event in PKD may be a defect
in the biosynthesis/secretion and or degradation of one or more
BM components (HS-PG) resulting in an altered composition
and assembly of the BM. The defect(s) could be transcriptional,
translational or post-translational. Altered mRNA expression of
BM components have been described in a murine model of
autosomal recessive PKD [281. Further attention should be
directed to possible enzymatic defects in the biosynthesis!
degradation of BM components, particularly sulfated PGs, and
to tubular cell-BM interactions in the pathogenesis of PKD.
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